Tasigna Atherosclerosis Lawsuit News

Specialty Pharmacists Bribed to Prescribe Tasigna

Generic drug competition led to specialty pharmacists refilling Gleevec prescriptions with the more potent Tasigna

Friday, July 6, 2018 - The Specialty Pharmacists Certification Board exists in order to "establish standards for Specialty Pharmacy that will improve patient care. According to their homepage, the organization's mission is to "Empower Specialty Pharmacists to maintain the highest quality standards to ensure safe and efficient patient care, establish clear standards of ethical practice, and ensure Specialty Pharmacists participate in ongoing professional development."

Specialty pharmacists dispense highly toxic chemotherapy drugs, so potent the drugs in and of themselves can cause death to the patient. Specialty pharmacists have an added responsibility to their patients to make sure that the patient understands every possible side effect that these deadly drugs could have. Specialty pharmacists broke this trust in the most heinous manner when they failed to exercise due diligence and make sure that Gleevec replacement drug Tasigna was safe for their most critical cancer patients.

In order to profit financially, specialty pharmacists looked the other way and ignored the side effects when they refilled their cancer patient's Gleevec prescriptions with the more potent and potentially lethal Tasigna. Hundreds of thousands of cancer patients took Tasigna and those that survived their cancer faced an even more deadly disease, atherosclerosis. Atherosclerosis from Tasigna is a rapidly forming buildup of fatty tissue called plaque wishing the inner walls of the body's major arteries causing a narrowing of the passageway and depriving critical parts of the body of receiving oxygen and nutrient-rich blood. As a result, Tasigna patients face the possibility of developing necrosis of the toes and feet requiring amputation, having a paralyzing stroke, or worse of all, sudden death from heart attack.

Cancer of all kinds is the most serious of diseases we in America face and Chemotherapy is one of the more serious if not the most serious drugs doctors prescribe to patients. Tasing cancer/atherosclerosis patients facing an uncertain medical future and suffering from atherosclerosis are urged to consult with a Tasigna atherosclerosis attorney to see if they qualify to file a claim against the maker of the drug, Swiss pharmaceutical giant Novartis AG. Novartis has already been fined $1 billion dollars and paid roughly half of that amount to settle claims that their marketing representatives deliberately looked the other way and did not make specialty pharmacists aware of the deadly risks Tasigna posed to their patients over the relatively safe and effective Gleevec, once considered in oncology circles as a wonder drug. Tasigna was developed to replace Novartis' bestselling breakthrough anti-cancer drug Gleevec, a drug that was generating millions of dollars in revenue every year for Novartis. Gleevec's patient was soon to expire and Novartis would not allow generic drug competition to erode their market share and profits. The company's drug sales reps began a marketing program of cash bonuses and incentives to incentivize specialty pharmacists to refill Gleevec prescriptions with Tasigna. Specialty pharmacists were bribed to conduct phony educational clinics and were paid cash incentives if they sold the most Tasigna each month.

Source: http://www.spcboard.org/about-spcb/

More Recent Tasigna Atherosclerosis Lawsuit News:

Lawyers for Tasigna Atherosclerosis Lawsuits

Attorneys handling Tasigna lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Tasigna lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Tasigna lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.